Literature DB >> 2441156

Plasma immunoreactive atrial natriuretic peptide levels after subcutaneous alpha-hANP injection in normal humans.

I G Crozier, M G Nicholls, H Ikram, E A Espiner, T G Yandle.   

Abstract

The plasma hormone and urine effects of 100 micrograms of alpha-human atrial natriuretic peptide (alpha-hANP) given by subcutaneous (s.c.) injection, were studied in eight healthy male volunteers. A control s.c. injection was administered on a separate day, and the study was single-blind. The peak immunoreactive atrial natriuretic peptide (IR-ANP) level of 29.4 +/- 4.4 pmol/L reached at 5 min was threefold higher than on the control day. Area under the IR-ANP response curve was approximately 1/32 of that after the same dose of alpha-hANP given by intravenous (i.v.) injection. alpha-hANP s.c. injection was not associated with significant effects on plasma renin activity (PRA), plasma aldosterone, or urine electrolyte excretion. It was concluded that only a small percentage of intact alpha-hANP is absorbed into the circulation after s.c. injection. With the dose of peptide and the injection vehicle chosen, alpha-hANP had little or no biological effect.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2441156     DOI: 10.1097/00005344-198707000-00010

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  2 in total

Review 1.  Intranasal drug delivery. Potential advantages and limitations from a clinical pharmacokinetic perspective.

Authors:  A E Pontiroli; A Calderara; G Pozza
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

Review 2.  Natriuretic Peptide-Based Novel Therapeutics: Long Journeys of Drug Developments Optimized for Disease States.

Authors:  Tomoko Ichiki; Atsushi Jinno; Yoshihisa Tsuji
Journal:  Biology (Basel)       Date:  2022-06-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.